SCHEMBL26089093

SCHEMBL26089093

COc1ncccc1-c1cc2ccncc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.44
BTK Q06187 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PDE5A O76074 2/20 0.41
AURKA O14965 2/20 0.40
TTK P33981 2/20 0.40
AURKB Q96GD4 2/20 0.40
INCENP Q9NQS7 1/20 0.40
CYP19A1 P11511 1/20 0.40
CLK2 P49760 1/20 0.40
CLK3 P49761 1/20 0.40
DYRK1A Q13627 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26088530 0.89 LOXL2 (0.47) LOXL2BTKKDM4EMEN1ALDH1A1
SCHEMBL537355 0.85 RAB9A (0.61) LOXL2BTKKDM4EMEN1ALDH1A1
SCHEMBL26087406 0.81 KDM4E (0.68) KDM4EMEN1ALDH1A1MAPTHPGD
SCHEMBL29079924 0.80 LOXL2 (0.44) LOXL2BTKKDM4EMEN1ALDH1A1
SCHEMBL24343877 0.79 LOXL2 (0.43) LOXL2BTKKDM4EMEN1ALDH1A1
SCHEMBL29535235 0.79 LOXL2 (0.43) LOXL2BTKKDM4EMEN1ALDH1A1
SCHEMBL5448565 0.78 ITK (0.54) LOXL2BTKKDM4EMEN1ALDH1A1
SCHEMBL26426630 0.76 PDE5A (0.67) BTKKDM4EALDH1A1HPGDRAB9A
SCHEMBL15886938 0.74 KDM4E (0.55) KDM4EMEN1ALDH1A1MAPTHPGD
SCHEMBL21565997 0.74 TLR8 (0.47) KDM4EMEN1ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2026-03-17 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
EP-4110777-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) 2023-01-04 EP disclosed
CN-115175909-A Pyrrolopyridine and imidazopyridine antiviral compounds 鲁汶天主教大学 2022-10-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS SARS1, TPI1, TPMT LOXL2 4779/4885BTK 3571/4885KDM4E 3519/4885
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds SARS1, TPMT, ZC3HAV1 LOXL2 2862/4885BTK 3256/4885KDM4E 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.